Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company, is implementing a 1-for-15 reverse stock split.
The reverse split aims to enable Salarius to regain compliance with the $1.00 minimum closing bid price required for Nasdaq listing.
All outstanding options and warrants will be adjusted as a result of the reverse split.
Reverse Stock Split
Salarius is implementing a 1-for-15 reverse stock split to regain Nasdaq compliance.
Share Reduction
The reverse split will reduce outstanding shares from 7.6 million to around 509,000 shares.
Impact on Options
All outstanding options and warrants will be adjusted following the reverse split.
- The reverse split is a strategic move to maintain compliance and potentially attract more investors.
- Share reduction may lead to a clearer valuation of the company's stock.
- Adjusting options and warrants ensures fair treatment for all shareholders.
The reverse stock split demonstrates Salarius Pharmaceuticals' proactive approach to enhancing shareholder value and compliance with Nasdaq requirements.